Abstracts tagged "Anti-TNF therapy and psoriatic arthritis"

Abstract Number: 598 • 2017 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab in Psoriatic Arthritis Patients By Prior Treatment Exposure and Disease Duration
Arthur Kavanaugh¹, Soumya D. Chakravarty^2,3, G. James Morgan⁴, M. Isabel Apaolaza⁵, Shelly Kafka², Elizabeth C. Hsia^6,7, Michael Song⁷, Yin You⁷ and Iain B. McInnes⁸, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Drexel University College of Medicine, Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Spring House, PA, ⁵Janssen Biologics BV, Leiden, Netherlands, ⁶University of Pennsylvania School of Medicine, Philadelphia, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸University of Glasgow, Glasgow, United Kingdom
Background/Purpose: To evaluate the efficacy of ustekinumab (UST) by prior treatment exposure and disease duration in adult PsA patients (pts) in the Phase 3 trials…
Abstract Number: 599 • 2017 ACR/ARHP Annual Meeting
Intravenous Golimumab in Adult Patients with Active Psoriatic Arthritis: Efficacy and Safety through Week 24
Arthur Kavanaugh¹, M. Elaine Husni², Diane D. Harrison³, Lilianne Kim³, Kim Hung Lo³ and Elizabeth C. Hsia⁴, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Rheumatology, Cleveland Clinic, Cleveland, OH, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA
Background/Purpose: The GO-VIBRANT study was designed to evaluate the safety and efficacy of intravenous (IV) golimumab (GLM) in adult patients (pts) with active PsA (biologic-naïve).…
Abstract Number: 632 • 2017 ACR/ARHP Annual Meeting
Long-Term Golimumab Retention Rate in Patients with Psoriatic Arthritis. Is Concomitant DMARD Important?
Belen Serrano¹, Carlos M Gonzalez², Roberto González³, Juan Gabriel Ovalles-Bonilla⁴, Juan Carlos Nieto², Julia Martínez-Barrio⁵, Iustina Janta², Larissa Valor³, Indalecio Monteagudo² and Francisco Javier López Longo⁶, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁴Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The efficacy of Golimumab (GLM) treatment in psoriatic arthritis (PsA) patients has been widely documented. The aim of this study was to analyze the…
Abstract Number: 1525 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database
Kurt R. Oelke¹, Rahul Garg², Peter Hur³, Olivier Chambenoit³, Amar Q. Majjhoo⁴, Stephani Gray⁵, Kate Higgins⁵ and Jacqueline B. Palmer³, ¹Rheumatic Disease Center, Glendale, WI, ²PRO Unlimited, Inc, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Shores Rheumatology, St. Clair Shores, MI, ⁵Truven Health Analytics, Cambridge, MA
Background/Purpose: To better understand the real-world efficacy of biologics for the treatment of psoriatic arthritis (PsA), there is a need to evaluate the persistence and…
Abstract Number: 2514 • 2016 ACR/ARHP Annual Meeting
Does Combination of Conventional Synthetic Disease Modifying Antirheumatic Drug with Anti-TNF Influence the Long Term Retention Compared to Anti-TNF Monotherapy in Psoriatic Arthritis? an Analysis from Rhumadata® over 12 Years
Isabelle Ferdinand¹, Louis Bessette², Josiane Bourré-Tessier³, Boulos Haraoui⁴, Jacques Brown⁵, Frédéric Massicotte³, Jean-Pierre Pelletier³, Jean-Pierre Raynauld⁴, Marie-Anaïs Rémillard⁶, Diane Sauvageau³, Angèle Turcotte⁵, Édith Villeneuve³ and Louis Coupal³, ¹University of Montreal, Montreal, QC, Canada, ²Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴1551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁵Rheumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁶Rhumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: In rheumatoid arthritis, it has been shown that anti-TNF therapy (TNFi) in combination with a conventional synthetic disease-modifying antirheumatic drug (csDMARD), often methotrexate (MTX),…
Abstract Number: 2767 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Evaluation of Modified Minimal Disease Activity upon Elimination of Each Component
Boulos Haraoui¹, Proton Rahman², Louis Bessette³, Philip Baer⁴, Suneil Kapur⁵, J. Antonio Avina-Zubieta⁶, Regan Arendse⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Allen J Lehman¹⁰, Francois Nantel¹¹, Brendan Osborne¹² and Cathy Tkaczyk¹², ¹University of Montreal, Montreal, QC, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁴Independent Rheumatology Practice, Scarborough, ON, Canada, ⁵University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁶Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA) is now considered an attainable target in psoriatic arthritis (PsA) reflecting a desired state of comprehensive disease control. MDA is…
Abstract Number: 2146 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing
Arthur Kavanaugh¹, Iain B. McInnes², Philip J. Mease³, Stephan Hall⁴, Hector Chinoy⁵, Alan J Kivitz⁶, Manmath Patekar⁷, Zailong Wang⁸ and Shephard Mpofu⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Monash University, Melbourne, Australia, ⁵University of Manchester, Manchester, United Kingdom, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: There remains an unmet need for additional treatment options for patients (pts) with psoriatic arthritis (PsA) who have had an inadequate response to or…
Abstract Number: 333 • 2013 ACR/ARHP Annual Meeting
Changes In Weight Associated With Tumour Necrosis Factor Inhibition In Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman¹ and Vinod Chandran¹, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with progressive joint damage and disability. In the last 15 years, tumour necrosis factor inhibitors…
Abstract Number: 1357 • 2012 ACR/ARHP Annual Meeting
Psoriatic Arthritis and Biologic Therapy: Treatment Response, Drug Survival and Outcome After Switching
Dinny Wallis¹, Deepak Jadon², William Tillett², Nicola Waldron², Charlotte Cavill³, Neil McHugh⁴ and Eleanor Korendowych², ¹Rheumatology, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath, United Kingdom, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Rheumatology, Bath Institute for Rheumatic Disease, Bath, United Kingdom, ⁴Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Data on longer term efficacy and tolerance of biologic therapies in psoriatic arthritis (PsA) are emerging. Persistence with the first TNF inhibitor (TNFi) at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].